請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64689
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張正琪(Cheng-Chi Chang),江俊斌(Chun-Pin Chiang) | |
dc.contributor.author | Wei-Ting Lai | en |
dc.contributor.author | 賴瑋婷 | zh_TW |
dc.date.accessioned | 2021-06-16T22:57:28Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-09 | |
dc.identifier.citation | References
1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-94. 2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54. 3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51: 15-36. 4. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75: 191-202. 5. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8. 6. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904. 7. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 2000; 157: 55-81. 8. Pepper MS. Lymph angiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7: 462–8. 9. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinze-Oustchoorn UE, Sotgia F, Lisanti MP. Ketones and lactate 'fuel' tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010; 9: 3506-14. 10. Dickens F, Simer F. The metabolism od normal and tumor tissue: The respiratory quotient, and the relationship of respiration to glycolysis. Biochem J 1930; 24: 1301-26. 11. Warburg O, Wind F, Negelein E. The metabolism of tumor in the body. J Gen Physiol 1927; 8: 519-30. 12. Warburg O. The reaction of ascites tumor cells to oxygen under high pressure. Arch Geschwulstforsch 1953; 6: 7-11. 13. Warburg O. Origin of cancer cells. Oncologia 1956; 9: 75-83. 14. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314. 15. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70. 16. Berridge MV, Tan AS. Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res 2010; 13: 139-41. 17. Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 2010; 30: 1303-18. 18. Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ 2011; 179: 1-12. 19. Dang CV. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. Sci Signal 2009; 2: pe75. 20. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities.Clin Cancer Res 2009; 15: 6479-83. 21. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-62. 22. Dang CV. Therapeutic Targeting of Myc-Reprogrammed Cancer Cell Metabolism. Cold Spring Harb Symp Quant Biol 2011. 23. Ralph SJ, Rodriguez-Enriquze S, Neuzil J, Saavedra E, Moreno-Sanchez R. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation – why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31: 145-170. 24. O’Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990; 10: 3569-77. 25. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 114: 1285-94. 26. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125-130. 27. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B. Proviral rearrangements and overexpression of a new cellular gene (NOV) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 1992; 12: 10-21. 28. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001; 54: 57-79. 29. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG,Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 1998; 95: 14717-22. 30. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248: 44-57. 31. Perbal B, Brigstock DR, Lau LF. Report on the second international workshop on the CCN family of genes. Mol Pathol 2003; 56: 80-5. 32. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80. 33. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999; 20: 189-206. 34. Ihn H. Pathogenesis of fibrosis: role of TGF-β and CTGF. Curr Opin Rheumatol 2002; 14: 681-695. 35. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549. 36. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A, Sawai T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002; 24: 677-683. 37. Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D, Zimmermann A, Buchler MW. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26: 420-427. 38. Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H, Wilda M, Iwamura T, Beger HG, Adler G, Gress TM. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999; 18: 1073-80. 39. Kubo M, Kikuchi K, Nashiro K, Kakinuma T, Hayashi N, Nanko H, Tamaki K. Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 1998; 139: 192-197. 40. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, Kawai A, Nakanishi T, Takigawa M, Inoue H. Expression of connective tissue growth factor in cartilaginous tumors. Cancer 2000; 89: 1466-73. 41. Chang CC, Shih JY, Jeng YM, Su JL, Lin BR, Chen ST, Chau YP, Yang PC, Kuo ML. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004; 96: 364-375. 42. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, Chau YP, Kuo ML. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology. 2005; 128(1): 9-23. 43. Moritani NH, Kubota S, Nishida T, Kawaki H, Kondo S, Sugahara T, Takigawa M. Suppressive effect of expressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett 2003; 192: 205-214. 44. Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MY, Jeng YM, Kuo ML, Chang CC. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 2011; 423: 1-11. 45. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumorigenesis. Cancer Cell Int 2003; 3: 15. 46. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, Fujii T. Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 1999; 274: 37461-6. 47. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-81. 48. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999; 19: 2958–66. 49. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, Cuezva JM: Alteration of the biogenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer, Biochem J 2004; 378: 17-20. 50. Kim MM, Clinger JD, Masayesva BG, Ha PK, Zahurak ML, Westra WH, Califano JA: Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res 2004; 10: 8512-15. 51. Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1999; 1410: 103-23. 52. Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol 2005; 37: 822-834. 53. Bonawitz ND, Clayton DA, Shadel GS. Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol Cell 2006; 24: 813-25. 54. Takamatsu C, Umeda S, Ohsato T, Ohno T, Abe Y, Fukuoh A, Shinagawa H, Hamasaki N, Kang D. Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein. EMBO Rep 2002; 3: 451-6. 55. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS, Clayton DA. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 1998; 18: 231-6. 56. Dong X, Ghoshal K, Majumder S, Yadav SP, Jacob ST. Mitochondrial transcription factor A and its downstream targets are up-regulated in a rat hepatoma. J Biol Chem 2002; 277: 43309-18. 57. Kidani A, Izumi H, Yoshida Y, Kashiwagi E, Ohmori H, Tanaka T, Kuwano M, Kohno K. Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction. Int J Oncol 2009; 35: 1435-40. 58. Toki N, Kagami S, Kurita T, Kawagoe T, Matsuura Y, Hachisuga T, Matsuyama A, Hashimoto H, Izumi H, Kohno K. Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch 2010; 456: 387-93. 59. Yoshida Y, Hasegawa J, Nezu R, Kim YK, Hirota M, Kawano K, Izumi H, Kohno K. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Sci 2011; 102: 578-82. 60. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-93. 61. Han B, Izumi H, Yasuniwa Y, Akiyama M, Yamaguchi T, Fujimoto N, Matsumoto T, Wu B, Tanimoto A, Sasaguri Y, Kohno K. Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem Biophys Res Commun 2011; 408:45-51. 62. Lee CH, Wu SB, Hong CH, Liao WT, Wu CY, Chen GS, Wei YH, Yu HS. Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers. Am J Pathol 2011; 178: 2066-76. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64689 | - |
dc.description.abstract | 目的 : 結締組織生長因子 (CTGF) 會抑制口腔鱗狀上皮細胞癌和非微小型細胞肺癌的轉移能力。我們假說結締組織生長因子可能藉由干擾癌症代謝而進一步調控癌症進程的發生。
實驗設計 : 利用海馬24生物能量分析儀來測量正常上皮細胞,口腔鱗狀細胞癌和非小型細胞肺癌的代謝。藉由博登細胞移行器實驗來分析癌細胞移行和侵入之實驗。 結果 : 本研究中發現結締組織生長因子降低糖解作用及氧化磷酸化 (P <0.05, P <0.01),更進一步減少細胞內三磷酸腺苷產物和乳酸堆積 (P <0.05, P <0.01),但在正常的上皮細胞中並沒有觀察到此現象。另外,也發現結締組織生長因子也會抑制氧化磷酸化的代償 (P <0.05),且減少粒線體活性。我們研究結果證明結締組織生長因子減少粒線體去氧核醣核酸拷貝數,而造成降低癌細胞移行和侵入之能力 (P <0.05, P <0.01)。同時,也發現粒線體轉錄因子A (mtTFA; TFAM) 蛋白表現與結締組織生長因子呈現負相關。在口腔鱗狀上皮細胞癌病人中也觀察到表現越多的粒線體轉錄因子A,病人的存活率就降低。有趣的是,藉由基因抑制內生性的粒線體轉錄因子A,會導致降低口腔鱗狀細胞癌和非小型細胞肺癌的癌細胞移行和侵入之能力。且如果再度表現粒線體轉錄因子A可以回復結締組織生長因子所抑制的癌症進程 (P <0.05, P <0.01)。 結論 : 結締組織生長因子在癌症代謝中扮演一個重要的調控者,是經由抑制粒線體轉錄因子A的表現,而降低了糖解作用以及氧化磷酸化,更進一步的導致口腔鱗狀上皮細胞癌和非微小型細胞肺癌的癌症進程之下降。 | zh_TW |
dc.description.abstract | Purpose:
Connective tissue growth factor (CTGF) has been shown to inhibit the metastatic activity of oral squamous cell carcinoma (OSCC) and non-small-cell lung carcinoma (NSCLC). We hypotheses that CTGF could interfere cancer metabolism and regulate tumor progression. Method: Metabolism pathways, including glycolysis and oxygen phosphorylation were measured by XF24 bioenergetic assay in normal epithelial, OSCC and NSCLC cells. Migration and invasion abilities of cells were performed by modified Boyden chamber assay. Result: We observed that CTGF reduced cellular ATP production and lactate levels (P <0.01, P <0.05), which may be caused by decreased glycolysis and oxygen phosphorylation in OSCC and NSCLC (P <0.05, P <0.01), but no significant effect on normal epithelial cells. This small secreted protein also inhibited oxidative phosphorylation compensation (P <0.05), and reduced mitochondrial activity. Our data demonstrated that CTGF decreased mitochondrial DNA copy numbers, which resulted in the repression of cancer cell migration and invasion abilities (P <0.01). We observed that mitochondrial transcription factor A (mtTFA; TFAM) protein expression negatively correlated with CTGF. mtTFA expression was positively associated with poor survival in OSCC patients (P <0.01). Interestingly, transiently knockdown endogenous mtTFA decreased OSCC and NSCLC migration and invasion abilities (P <0.01). mtTFA overexpression restored CTGF-inhibited OSCC and NSCLC progression in vitro and in vivo (P <0.05, P <0.01). Conclusion: CTGF, a key regulator of cancer metabolism, decreased cancer metabolism, including glycolysis and oxygen phosphorylation via inhibiting mtTFA expression, and resulted in a reduction in cancer progression in OSCC and NSCLC cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T22:57:28Z (GMT). No. of bitstreams: 1 ntu-101-R99450008-1.pdf: 1702338 bytes, checksum: 823751e2a55d95550379e136f2886b2b (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | Contents
Introduction …………………………………………..………………...1 Materials and Methods ……………………………...…………………4 Results……………………………………………….,………………....13 1. CTGF decreased cancer metabolism and ATP production in OSCC and NSCLC cell lines. 2. CTGF inhibited oxidative phosphorylation compensation in OSCC and NSCLC cells. 3. CTGF disabled mitochondrial function and property in OSCC and NSCLC cells. 4. Overexpression of mtTFA restored cancer progression in CTGF-transfectants. 5. Exogenous expression of mtTFA and CTGF-mediated inhibition of cancer progression in vivo. Discussion………………………………………………………………20 References ……………………………...………………………….…..24 Figures ……………………………..…………………………………..31 Tables ………………………………..…………………………………54 | |
dc.language.iso | en | |
dc.title | 結締組織生長因子於癌症代謝之影響 | zh_TW |
dc.title | Effects of Connective Tissue Growth Factor on Cancer Metabolism | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊慕華(Muh-Hwa Yang),郭彥彬(Mark Yen-Ping Kuo) | |
dc.subject.keyword | 口腔鱗狀上皮細胞癌,非微小型細胞肺癌,癌症進程,結締組織生長因子,粒線體轉錄因子A,代謝, | zh_TW |
dc.subject.keyword | OSCC,NSCLC,cancer progression,CTGF,mtTFA,metabolism, | en |
dc.relation.page | 54 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-09 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.66 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。